My site

ABU DHABI, United Arab Emirates - Tuesday, January 5th 2016 [ME NewsWire]

In its 11th meeting for 2015, the Higher Committee for Combating Drugs at the Ministry of Interior discussed ways to enhance cooperation and coordination with the National and Reserve Service Authority in the fight against drugs. This aims to protect national service conscripts and raise their awareness about the dangers of drug use and abuse.

The Higher Committee recently held its meeting under the chairmanship of Colonel Saeed Abdullah Al Suwaidi, Director General, Anti-Narcotics Federal Directorate General at the Ministry of Interior, in the conference room at the Anti-Narcotics Directorate General Headquarters at Dubai Police.

Colonel Al Suwaidi stressed the importance of integration between the competent authorities involved in the fight against drugs to reach the coveted goal. He pointed out that such meetings provide the opportunity to develop prevention, awareness, and treatment ... Read more »

Following a Dispute over Dinner Preparations

ABU DHABI, United Arab Emirates - Friday, January 1st 2016 [ME NewsWire]

A Nepalese truck driver died of wounds inflicted by stabbing with a sharp knife, after attempting to break up a fight that broke out between two of his Nepalese colleagues over dinner preparation. The dispute took place at a labor accommodation in the Western Region in Abu Dhabi.

Brigadier Ojail Ali Al Junaibi, Director of the Western Region Police Directorate at the Abu Dhabi Police, said that the directorate managed to arrest the suspect 35 minutes after receiving notification. “The directorate also seized the long-blade kitchen knife used in the crime, which the offender had concealed in the air conditioning unit,” he said.

Elaborating on the details of the crime, Brigadier Al Junaibi said that the Zayed City Police Station received notification from the Operations Room about a stabbing case at a labor accommodation in t ... Read more »

• Merck, Pfizer and Syndax will collaborate to investigate safety, tolerability and preliminary efficacy of avelumab and entinostat in advanced ovarian cancer

DARMSTADT, Germany & NEW YORK & WALTHAM, Mass. - Monday, January 4th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Merck, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T-cells), in patients with heavily pre-treated, recurrent ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types by the Merck-Pfizer Alliance. This is an exclusive agreement between the alliance and Syndax to study the combination of these two investigational agents in ovari ... Read more »

 Final study results demonstrate for the first time efficacy of long-lasting absorbable biosynthetic mesh in challenging hernia repairs; has potential to end biologics era in hernia repair

FLAGSTAFF, Ariz. - Tuesday, January 5th 2016 [ME NewsWire]

CORRECTION...by W. L. Gore & Associates

(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

NOW PUBLISHED IN THE ANNALS OF SURGERY: LONG-TERM FAVORABLE RESULTS DEMONSTRATE GORE BIO-A TISSUE REINFORCEMENT EFFICACY IN COMPLEX VENTRAL HERNIA REPAIRS

Final study results demonstrate for the first time efficacy of long-lasting absorbable biosynthetic mesh in challenging hernia repairs; has potential to end biologics era in hernia repair

W. L. Gore & Associates, Inc. (Gore) today announced final results of a long-term, prospective, multicenter study1 evaluating the use of GORE® BIO-A® T ... Read more »

Final study results of bioabsorbable mesh shows significant improvement in patient quality of life while offering cost-savings to hospitals and payors

FLAGSTAFF, Ariz. - Monday, January 4th 2016 [ME NewsWire]

(BUSINESS WIRE)-- W. L. Gore & Associates, Inc. (Gore) today announced final results of a long-term, prospective, multicenter study evaluating the use of GORE® BIO-A® Tissue Reinforcement, a bioabsorbable mesh, in complex ventral hernia (CVH) repair in patients with contaminated fields. Michael Rosen, MD, Cleveland Clinic, the lead investigator of the study, published the research in the Annals of Surgery.

Patients scheduled to undergo CVH repair often have a poor quality of life preoperatively because of a GI fistula, mesh infection, or non-healing abdominal wound. With a sample size of more than 100 patients, these study results showed improved quality of life and a favorable hernia recurrence rate of only 17 percent after 24 months when us ... Read more »

BEDFORD, N.H. - Monday, January 4th 2016 [ME NewsWire]

(BUSINESS WIRE)-- In the morning of January 4 EDT, Segway Inc. (hereinafter “Segway”) officially announced an expansion of its business and released its new corporate visual identity (VI) system.

Following a lengthy research and development process, Segway recently formally added personal robotics to its business lines, thereby expanding its business to include two major categories: Segway PT (Personal Transportation) and Segway Robotics. In 2016, Segway will work with Intel and Xiaomi to enter the home service robotics market. Segway seeks to create a futuristic concept by integrating existing technological proposals—a move that is critical for Segway’s personal robotics business. Following the business expansion, Segway will no longer be a brand limited solely to one category of personal mobility products, but will become a comprehensive technology brand that encompasses personal transpo ... Read more »

DUBLIN & BOSTON - Monday, January 4th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Fleetmatics Group PLC (NYSE:FLTX), a leading global provider of mobile workforce solutions for service-based businesses of all sizes delivered as software-as-a-service (SaaS), today announced that it will release financial results for the fourth quarter of 2015 on Wednesday, February 24, 2016 after the market closes. Members of the Company’s management team plan to host a live conference call and webcast at 5:00 p.m. Eastern Time on that day to discuss the financial results as well as management’s outlook for the business. The conference call may be accessed in the United States by dialing 1.800.553.5275 and using access code “FLTX”. The conference call may be accessed outside of the United States by dialing +1.612.332.0725 and using access code “FLTX”. The conference call will be simultaneously webcast on the Company’s investor relations website, which ca ... Read more »

Launch of the 1st clinical trial on Humans

MULHOUSE, France - Monday, January 4th 2016 [ME NewsWire]

(BUSINESS WIRE)-- After European authorization was obtained this summer, the French and British regulatory agencies have authorized CellProthera to begin its first phase I/IIB clinical trial in Humans, starting January, 2016.

Recently, CellProthera presented its regenerative cardiac therapy to Marisol TOURAINE, French Minister of Social Affairs, Health and Women's Rights, before a large audience of journalists, investors, doctors and cabinet members. This initiative firmly places CellProthera among the key French startups in health services.

Upcoming launch of the 1st clinical trial on Humans

Two cell therapy centers devoted to clinical trials - EFS ABG Nantes for France and Newcastle Cellular Therapies Facility for UK - have already been equipped with the StemXpand® automated system developed by CellProthera. Within nine days, the auto ... Read more »